Synaptogenix Inc (SNPX)

[noretreat]

Neurotrope Bioscience to Release Results From Phase 2 Clinical Trial in Moderate to Severe Alzheimer's Disease on May 1, 2017Company to Host Investor Conference Call
PR NEWSWIRE 6:30 AM ET 4/28/2017

NEW YORK , April 28, 2017 /PRNewswire/ -- Neurotrope, Inc. , a clinical-stage biopharmaceutical company developing novel therapies for neurodegenerative diseases, including Alzheimer's disease, will issue a press release announcing results of top-line data from its 148 patient, Phase 2 clinical trial in moderate to severe Alzheimer's Disease, on Monday May 1, 2017, at 6:30 am, Eastern Time. A conference call will follow at 8:30 am Eastern Time on that date.

The dial-in information to access the live call is listed below:

Participant Toll Free Dial-In Number: [phone]
Participant International Dial-In Number: [phone]
Conference ID: 16070779

The dial-in information to access the call replay, available for 30 days after the live call, is listed below:

Replay Toll Free Dial-In Number: [phone]
Replay International Dial-In Number: [phone]
Conference ID: 16070779

Callers should dial in approximately 10 minutes before the live call begins